Conduit Pharmaceuticals Inc. (NASDAQ:CDT – Get Free Report) Director Andrew Regan sold 1,005,200 shares of the company’s stock in a transaction that occurred on Monday, July 15th. The shares were sold at an average price of $0.25, for a total value of $251,300.00. Following the sale, the director now owns 11,936,119 shares in the company, valued at approximately $2,984,029.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Andrew Regan also recently made the following trade(s):
- On Wednesday, July 17th, Andrew Regan sold 1,514,100 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.26, for a total value of $393,666.00.
- On Friday, July 12th, Andrew Regan sold 1,389,820 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.25, for a total value of $347,455.00.
- On Wednesday, July 10th, Andrew Regan sold 150,000 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.33, for a total transaction of $49,500.00.
- On Monday, July 8th, Andrew Regan sold 35,923 shares of Conduit Pharmaceuticals stock. The stock was sold at an average price of $0.51, for a total transaction of $18,320.73.
- On Wednesday, July 3rd, Andrew Regan sold 1,000 shares of Conduit Pharmaceuticals stock. The shares were sold at an average price of $0.64, for a total transaction of $640.00.
Conduit Pharmaceuticals Price Performance
Shares of NASDAQ CDT opened at $0.14 on Friday. Conduit Pharmaceuticals Inc. has a 12-month low of $0.11 and a 12-month high of $22.00. The stock’s 50 day simple moving average is $0.17 and its 200 day simple moving average is $1.76.
Wall Street Analyst Weigh In
Separately, Berenberg Bank raised shares of Conduit Pharmaceuticals to a “strong-buy” rating in a report on Friday, July 26th.
Read Our Latest Stock Analysis on CDT
Conduit Pharmaceuticals Company Profile
Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
See Also
- Five stocks we like better than Conduit Pharmaceuticals
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Take Advantage of Village Farms Stock as Cannabis Market Evolves
- The How and Why of Investing in Gold Stocks
- MarketBeat Week in Review – 9/16 – 9/20
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Don’t Miss These 3 Retail Stocks for Fall Gains
Receive News & Ratings for Conduit Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conduit Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.